NCT05516914 2025-11-28
A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT06456138 2024-06-13
Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC
Shanghai Chest Hospital
Phase 1/2 Not yet recruiting
NCT04985721 2023-03-15
IMPARP-HRD
Peter MacCallum Cancer Centre, Australia
Phase 2 Unknown
NCT05241132 2022-02-15
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
Shanghai Changzheng Hospital
Phase 2 Unknown